Subtype
Pituitary Neuroendocrine Tumor of PIT1-Lineage
CI-CAN-00006427Explore in graph →
Non-malignant2 active trials
- NCIt
- C187086
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006427Explore in graph →
Clinical trials
22 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001595 | An Investigation of Pituitary Tumors and Related Hypothalmic Disorders | recruiting | — | 2,000 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07463235 | Safety and Potency of a High Cabergoline Dosage in Microprolactinomas(SPARAGMOS) | recruiting | Phase 3 | 70 | University of Sao Paulo General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07268183 | How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors(OEMacroPrL) | recruiting | — | 180 | Hospices Civils de LyonOTHER | 1 | Jan 22, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials
| NCT06936813 | The PROMISE Survey | active not recruiting | — | 530 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04106531 | Validation of a Quality of Life Metric "Prolac-10"(Prolac-10) | terminated | — | 8 | Ohio State UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07045935 | Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment(ProBOLIC) | recruiting | Phase 4 | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05236829 | Exercise Capacity and Physical Activity Level in Prolactinoma Patients | completed | — | 38 | Hacettepe UniversityOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT04107480 | PRolaCT - Three Prolactinoma RCTs | unknown | Phase 4 | 880 | Leiden University Medical CenterOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03457389 | Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma | unknown | N/A | 68 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT03474601 | Seoul National University Pituitary Disease Cohort Study(SNU-PIT) | unknown | — | 1,600 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03717454 | Dopamine D2 Receptors(D2R) Imaging in Prolactinomas | unknown | N/A | 50 | Zhebao WuOTHER | 0 | Nov 20, 2018 | clinicaltrials |
| NCT03400865 | Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas | unknown | N/A | 30 | Zhebao WuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01504399 | Rhinological Outcomes in Endonasal Pituitary Surgery | completed | — | 235 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03353025 | Study on Therapy of Non-invasive Prolactinoma(TNAPA) | unknown | N/A | 394 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01775332 | Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools | unknown | N/A | 60 | Unity Health TorontoOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00697814 | Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | completed | Phase 2 | 15 | Federal University of São PauloOTHER | 1 | Jun 16, 2008 | clinicaltrials |
| NCT00460616 | Cardiac Valve Complications in Prolactinomas Treated With Cabergoline(ValveCab) | completed | — | 50 | Federico II UniversityOTHER | 1 | Apr 16, 2008 | clinicaltrials |
| NCT00481299 | Insulin Resistance in Women With Prolactinoma | completed | — | 2,004 | Universidade Federal do Rio de JaneiroOTHER | 1 | Jun 1, 2007 | clinicaltrials |